CSL to return cash after Talecris deal aborted

SYDNEY, June 9 (Reuters) - Australian blood products group CSL Ltd (CSL.AX) will return up to around A$1.6 billion ($1.26 billion) to shareholders through on-market share buybacks after aborting its planned takeover of U.S. rival Talecris Biotherapeutics Holdings Corp, CSL said on Tuesday.

CSL said it would buy back up to 54.86 million shares, or about 9 percent of its issued share capital, noting that the buy-back programme would cost about A$1.59 billion at the company's last-traded stock price of A$28.98.

(Reporting by Mark Bendeich; Editing by Jonathan Standing) ($1=1.274 Australian Dollar)